Zai Lab Limited (ZLAB)
(Real Time Quote from BATS)
$18.51 USD
+0.51 (2.83%)
Updated Jul 16, 2024 01:16 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ZLAB 18.51 +0.51(2.83%)
Will ZLAB be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ZLAB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ZLAB
Best Momentum Stocks to Buy for July 10th
New Strong Buy Stocks for July 10th
ZLAB: What are Zacks experts saying now?
Zacks Private Portfolio Services
What Makes Zai Lab Limited Unsponsored ADR (ZLAB) a New Buy Stock
Ultragenyx (RARE) Surges 10.3%: Is This an Indication of Further Gains?
Seagen's (SGEN) Late-Stage Cervical Cancer Study Meets Goals
Other News for ZLAB
Zai Lab and argenx Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China
Zai Lab-Supported Study Published in Cell Provides New Insights with Potential to Improve Treatment of HRD-Positive Ovarian Cancers, Including Through Combination PARP Inhibitor and CCR8 Therapy
Zai Lab to Announce Second Quarter 2024 Financial Results and Recent Corporate Updates on August 6, 2024
Insider Selling: Chairperson & CEO Ying Du Sells Shares of Zai Lab Ltd (ZLAB)
Zai Lab Announces Dr. Harald Reinhart to Retire as Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases; Dr. Rafael Amado to be Appointed President, Head of Global R&D